Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

(NYSE: NYSE:NVRO), a global medical device firm specializing in chronic pain treatment, for approximately $250 million in cash. The acquisition, announced today, will see Globus Medical buy all ...

expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic pain treatment solutions. Management reaffirmed 2025 revenue guidance of $2 ...

Globus Medical, Inc., a medical device company ... such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral ...